BC
ISEE

Broadfin Capital’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Broadfin Capital’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-410,000
Closed -$18.9M – 71
2016
Q3 		$18.9M Buy
410,000
+232,600
+131% +$13.1M 1.7% 17
2016
Q2 		$9.05M Buy
+177,400
New +$8.81M 0.88% 30
2014
Q1 		– Sell
-150,000
Closed -$4.85M – 89
2013
Q4 		$4.85M Buy
+150,000
New +$4.45M 0.64% 40

Other funds holding ISEE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Broadfin Capital's ISEE Position: Q4 2016 in Review

Broadfin Capital sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q4 2016, closing a stake of 410,000 shares — an estimated $18.9M sold.

Broadfin Capital first reported a position in ISEE in Q4 2013 and held it in 3 quarters. The position peaked at $18.9M in Q3 2016. 137 funds tracked by Wall St. Rank hold ISEE as of Q4 2016.

  • Broadfin Capital reported no remaining IVERIC bio, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Broadfin Capital sold 410,000 IVERIC bio, Inc. Common Stock shares in Q4 2016, an estimated $18.9M.
  • Broadfin Capital first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 3 quarters.
  • Broadfin Capital's IVERIC bio, Inc. Common Stock position peaked at $18.9M in Q3 2016.
  • 137 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q4 2016.

Based on Broadfin Capital's 13F filing for Q4 2016, filed 14 Feb 2017.